FewerJobs.
All jobs

Director, Medical Information, Japan

Revolution Medicines - Remote (Japan)

Posted May 15, 2026

Benefits

Parental leave
Not verified
Non-birth-parent leave
Not verified
Family-building benefits
  • Fertility benefits: Not verified
  • Adoption assistance: Not verified
  • Surrogacy assistance: Not verified
Mental health support
Not verified
Relocation assistance
Not verified
Childcare support
Not verified
Learning budget
Not verified
Verification
Not verified checked Jun 7, 2026
Salary
Not verified
401(k) match
Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)
$81,444 U.S. median for this role
Projected growth (BLS Employment Projections)
+6.9% - Faster than average

Matched to SOC 29-1141 - Healthcare aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function
Healthcare From the posting source checked Jun 20, 2026
Seniority
Director Plus From the posting source checked Jun 20, 2026
Work mode
Remote From the posting source checked Jun 20, 2026
In-office days
0 days From the posting source checked Jun 20, 2026

Schedule

Shift type
Not verified
Weekend work
Not verified

Company

Equity
Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter
Not verified
Assessment
Not verified
Deadline
Not stated

Where they hire

State eligibility is not yet verified.

About this role

Director, Medical Information, Japan Remote (Japan) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a motivated and experienced professional to join our team as a Director of Medical Information supporting Japan. This role focuses on ensuring the delivery of timely, accurate, and evidence-based responses to healthcare professionals (HCPs), patients, and caregivers. As a key member of the Medical Affairs team, you will oversee the creation and management of medical information content, provide scientific and operational oversight of Japan medical information call center team, contribute to medical booth asset creation, and contribute to dossier development and review. This role will also provide Medical Information support at scientific congresses and collaborate cross-functionally to support both pipeline assets and companion diagonstics. The ideal candidate is a skilled communicator with a strong scientific background and can manage projects in a dynamic environment. This role will report to the Head of Medical Information within the Global Medical Excellence team. Key Responsibilities: -

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.

Apply at revmed.com

Apply link not verified; last-live date unavailable.

What verified means

Verified means a displayed claim has field-level provenance to a source FewerJobs pulled: a government or employer source, or the original job posting. Posting-sourced facts are employer-stated and are labeled separately from government records.